| Literature DB >> 22215056 |
Adam Wright1, Justine Pang, Joshua C Feblowitz, Francine L Maloney, Allison R Wilcox, Karen Sax McLoughlin, Harley Ramelson, Louise Schneider, David W Bates.
Abstract
BACKGROUND: Accurate clinical problem lists are critical for patient care, clinical decision support, population reporting, quality improvement, and research. However, problem lists are often incomplete or out of date.Entities:
Mesh:
Year: 2012 PMID: 22215056 PMCID: PMC3384110 DOI: 10.1136/amiajnl-2011-000521
Source DB: PubMed Journal: J Am Med Inform Assoc ISSN: 1067-5027 Impact factor: 4.497
Figure 1Screenshot of problem inference alerts.
Figure 2Participant flow for study clusters (subclinic randomization). Because randomization was carried out at the subclinical level, a small number of patients (n=3849) appear in both arms of the study.
Demographics of patients seen in control and intervention clinics
| Demographic characteristic | Control | Intervention | p Value |
| Age (years), mean (SD) | 49.6 (20.0) | 47.7 (19.6) | <0.0001 |
| Sex (female) | 61.4% | 68.0% | <0.0001 |
| Race or ethnicity | |||
| American Indian | 0.12% | 0.17% | <0.0001 |
| Asian/Pacific Islander/Native Hawaiian | 2.4% | 3.0% | |
| Black | 14.2% | 11.4% | |
| Hispanic | 17.1% | 17.6% | |
| White | 57.6% | 58.6% | |
| Other | 0.61% | 0.55% | |
| Declined/unknown | 7.9% | 8.7% | |
| Language | |||
| English | 85.7% | 85.3% | <0.0001 |
| Spanish | 8.8% | 10.0% | |
| Other | 5.5% | 4.6% | |
| Primary insurance | |||
| Commercial | 59.6% | 64.1% | <0.0001 |
| Medicare | 22.3% | 17.7% | |
| Medicaid | 14.0% | 14.6% | |
| Other/self pay | 4.0% | 3.6% | |
| Income (US$), mean (SD) | 56 350 (20 686) | 59 663 (23 737) | <0.0001 |
Alert acceptance rates by condition
| Disease | Unique rule firings | Number of alerts accepted | Number of alerts over-ridden | Number of alerts ignored | Overall acceptance rate (%) |
| Attention deficit hyperactivity disorder | 225 | 102 | 31 | 194 | 45.3 |
| Asthma/chronic obstructive pulmonary disease | 2452 | 842 | 585 | 1867 | 34.3 |
| Breast cancer | 245 | 116 | 36 | 209 | 47.3 |
| Coronary artery disease | 1069 | 439 | 274 | 795 | 41.1 |
| Congenital coagulopathy | 45 | 15 | 19 | 26 | 33.3 |
| Congestive heart failure | 914 | 331 | 279 | 635 | 36.2 |
| Diabetes mellitus | 1330 | 519 | 324 | 1006 | 39.0 |
| Glaucoma | 336 | 187 | 40 | 296 | 55.7 |
| Hypertension | 5362 | 2281 | 1029 | 4333 | 42.5 |
| Hyperthyroidism | 141 | 46 | 39 | 102 | 32.6 |
| Hypothyroidism | 1291 | 639 | 220 | 1071 | 49.5 |
| Myasthenia gravis | 15 | 3 | 6 | 9 | 20.0 |
| Osteoporosis/osteopenia | 2285 | 962 | 475 | 1810 | 42.1 |
| Rheumatoid arthritis | 231 | 61 | 78 | 153 | 26.4 |
| Renal failure/insufficiency | 991 | 413 | 148 | 843 | 41.7 |
| Sickle cell disease | 12 | 1 | 7 | 5 | 8.3 |
| Stroke | 99 | 54 | 14 | 85 | 54.5 |
| Total | 17 043 | 7011 | 3604 | 13 439 | 41.1 |
Overall acceptance rate combines alerts that were accepted after being displayed multiple times (number of alerts accepted/unique rule firings).
Figure 3Cumulative number of study problems added during pre-intervention and intervention periods.
Total study problems recorded during pre-intervention and intervention periods with unadjusted and adjusted ORs
| Problem | Pre-intervention period | Intervention period | Unadjusted | Adjusted | ||||
| Control | Intervention | Control | Intervention | Relative rate | p Value | OR | p Value | |
| Attention deficit hyperactivity disorder | 66 | 72 | 69 | 157 | 2.09 | <0.0001 | 2.23 | <0.0001 |
| Asthma/chronic obstructive pulmonary disease | 498 | 503 | 529 | 1291 | 2.42 | <0.0001 | 2.98 | <0.0001 |
| Breast cancer | 151 | 123 | 180 | 246 | 1.68 | 0.0004 | 1.78 | <0.0001 |
| Coronary artery disease | 164 | 134 | 178 | 576 | 3.96 | <0.0001 | 4.66 | <0.0001 |
| Congenital coagulopathy | 4 | 4 | 5 | 19 | 3.80 | 0.0133 | 2.06 | 0.0384 |
| Congestive heart failure | 64 | 50 | 97 | 373 | 4.92 | <0.0001 | 7.56 | <0.0001 |
| Diabetes mellitus | 597 | 446 | 535 | 814 | 2.04 | <0.0001 | 1.97 | <0.0001 |
| Glaucoma | 53 | 74 | 61 | 263 | 3.09 | <0.0001 | 3.78 | <0.0001 |
| Hypertension | 1019 | 863 | 1031 | 3082 | 3.53 | <0.0001 | 4.12 | <0.0001 |
| Hyperthyroidism | 86 | 96 | 72 | 124 | 1.54 | 0.0308 | 1.30 | 0.2928 |
| Hypothyroidism | 207 | 237 | 205 | 823 | 3.51 | <0.0001 | 3.99 | <0.0001 |
| Myasthenia gravis | 4 | 2 | 3 | 5 | 3.33 | 0.2850 | 2.10 | 0.114 |
| Osteoporosis/osteopenia | 513 | 483 | 582 | 1521 | 2.78 | <0.0001 | 3.40 | <0.0001 |
| Rheumatoid arthritis | 27 | 21 | 24 | 75 | 4.02 | <0.0001 | 3.97 | <0.0001 |
| Renal failure/insufficiency | 84 | 73 | 87 | 521 | 6.89 | <0.0001 | 8.22 | <0.0001 |
| Sickle cell disease | 9 | 12 | 13 | 23 | 1.33 | 0.3538 | 1.66 | 0.2897 |
| Stroke | 51 | 37 | 68 | 103 | 2.09 | 0.0023 | 2.35 | 0.0002 |
| Total | 3597 | 3230 | 3739 | 10 016 | 2.98 | <0.0001 | 3.43 | <0.0001 |
Unadjusted comparison based on unadjusted relative rate of problem list addition, as described in the methods sections.
Adjusted comparison based on Poisson regression model for an interrupted time series.